Mothers against decapentaplegic homolog (SMAD) (SMAD)

Mothers against decapentaplegic homolog (SMAD) proteins are a family of intracellular signal transducers and transcription factors that serve as the primary effectors of the transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) signaling pathways. In humans, the family consists of eight members (SMAD1 to SMAD7 and SMAD9), classified into receptor-regulated SMADs (R-SMADs), common-partner SMADs (Co-SMADs), and inhibitory SMADs (I-SMADs). Upon activation by transmembrane serine/threonine kinase receptors, R-SMADs are phosphorylated, form a heteromeric complex with SMAD4 (the Co-SMAD), and translocate into the nucleus to modulate the expression of target genes involved in cell growth, differentiation, and apoptosis. Dysregulation of the SMAD pathway is a hallmark of several pathologies, particularly cancer and fibrotic diseases. In oncology, SMAD4 is frequently inactivated or deleted in pancreatic and colorectal cancers, leading to uncontrolled proliferation and metastasis. In fibrotic conditions, such as pulmonary or renal fibrosis, overactivation of SMAD2/3 signaling drives the excessive production of extracellular matrix. Therapeutic targeting of SMADs often involves the use of small molecule inhibitors or ligand traps that block the upstream kinase activity or the phosphorylation status of the proteins themselves. While they are promising targets for treating advanced-stage diseases, the ubiquitous nature of SMAD signaling poses significant challenges for achieving therapeutic selectivity without interfering with essential physiological homeostatic processes.

Other names

SMAD family proteinsMADHMAD homologSMA- and MAD-related proteinsSMAD transcription factors

Inhibition of phosphorylation by TGF-beta/BMP receptors, prevention of nuclear translocation, or modulation of SMAD-dependent gene transcription.